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Background
Omenn Syndrome (OS) is a rare inherited disorder pre-
senting with early-onset generalized erythrodermia, alope-
cia, chronic diarrhea, lymphoadenopathy, failure to thrive,
and recurrent infections. The immunological phenotype is
characterized by eosinophilia, virtual absent circulating B
cells but elevated IgE serum levels. T cells are normal or
increased and display a highly restricted, oligoclonal TCR
repertoire. Because of overwhelming infections and loss of
proteins, the disease is fatal, unless treated with allogeneic
bone marrow transplantation, which is variably successful.
We have previously demonstrated that mutations in either
RAG1 and RAG2, impairing, but not abolishing, the first
steps of V(D)J recombination, are the main cause of this
syndrome [1]. Nonetheless, a compelling explanation for
the autoimmune features of OS has proven elusive. The
pathogenesis is likely multifactorial. We have shown that
the reduced thymopoiesis in OS patients is accompanied
by defects in thymic epithelial cell maturation and/or
homeostasis, impaired expression of autoimmune regulator
(aire) protein and poor generation of thymic CD4+CD25
+Foxp3+ natural regulatory T cells [2,3]. While these
observations emphasize the potential role of T cell toler-
ance impairments in sustaining the immune dysregulation
of OS, a possible contribution of defects in other immune
cells, such as antigen presenting cells, has not been investi-
gated. In addition, numerous questions remain surround-
ing the disease pathogenesis. To gain insights into the
mechanisms underlying autoimmunity, we have recently
generated a murine model (the Rag2
R229Q/R229Qmouse) car-
rying in Rag2 gene a mutation responsible for OS in many
patients. This mouse model recapitulates the phenotype
and many of the clinical manifestations of OS patients [4].
We have used this model to further investigate T and B
cell contribution in the pathogenesis of autoimmune mani-
festations in OS.
Results
To characterize B cell defects and their contribution to the
disease, we studied the hypomorphic R229Q rag2 mice.
Consequent to a developmental arrest at the early pro-B
stage, peripheral B cell pool in Rag2
R229Q/R229Qmouse
showed a strong reduction in size and an altered composi-
tion. The majority of B cells retained an immature pheno-
type, while a few IgM
+ B cells displayed higher expression
of activation markers. Nonetheless, a normal or even
increased compartment of immunoglobulin secreting cells
is generated. The exaggerated activation and plasmacytic
differentiation of rag2
R229Q B cells correlated to elevated
levels of homeostatic cytokines, leading to increased
Blimp-1 and Xbp-1 expression. Moreover, analysis of
serum autoantibodies revealed the presence of anti-
dsDNA, suggestive of defaults in B-cell selection and toler-
ance. Collectively, our findings for the first time point out
a role for B cells in OS pathology [5].
Conclusions
In conclusion, we show that in OS persistent inflammation
favours the expansion and the exaggerated plasmacytic dif-
ferentiation of an oligoclonal B cell population with auto-
reactive potential. Thus, we propose that breakdown in B
cell selection and tolerance contributes to the develop-
ment of autoimmunity and atopy in this disease.
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